Evidence map›Paper›PMID 25861015›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2015

Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061.

Iris Chen, Matthew B Connor, William Clarke, Mark A Marzinke, Vanessa Cummings, Autumn Breaud, Jessica M Fogel, Oliver Laeyendecker, Sheldon D Fields, Deborah Donnell and 10 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. National Landscape of Human Immunodeficiency Virus-Positive Deceased Organ Donors in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 1 country.

Iris Chen*Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ‡Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD; §Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ‖College of Nursing and Health Sciences, Florida International University, Miami, FL; ¶Department of Global Health, University of Washington, Seattle, WA; #Science Facilitation Department, FHI 360, Durham, NC; **Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; ††Department of Family Medicine, University of California Los Angeles, Los Angeles, CA; ‡‡Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA; §§Department of Epidemiology and Biostatistics, The George Washington University, Washington, DC; ‖‖Department of Medicine, Harlem Hospital, Mailman School of Public Health, Columbia University, New York, NY; ¶¶Graduate School of Social Work, Loyola University Chicago, Chicago, IL; ##Division of Fenway Health, The Fenway Institute, Boston, MA; ***Infectious Disease Division, Beth Israel Deaconess Medical Center, Boston, MA; †††Department of Medicine, Harvard Medical School, Boston, MA; and ‡‡‡Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY.
Matthew B Connor
William Clarke
Mark A Marzinke
Vanessa Cummings
Autumn Breaud
Jessica M Fogel
Oliver Laeyendecker
Sheldon D Fields
Deborah Donnell
Sam Griffith
Hyman M Scott
Steven Shoptaw
Carlos del Rio
Manya Magnus
Sharon Mannheimer
Darrell P Wheeler
Kenneth H Mayer
Beryl A Koblin
Susan H Eshleman
Johns Hopkins University · USJohns Hopkins Medicine · USCancer Research Center · USColumbia University · USEmory University · USFamily Health International 360 · USFlorida International University · USGeorge Washington University · USHarvard University · USInfectious Disease Research Institute · USLoyola University Chicago · USNational Institutes of Health · USNew York Blood Center · USSan Francisco Department of Public Health · USUniversity of California, Los Angeles · US

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
Emory HIV/AIDS Clinical Trials UnitUM1AI069418 · NIAID · EMORY UNIVERSITY · PI Colleen F Kelley · 2012 to 2026
$46.0M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
TRAINEESHIPS IN AIDS PREVENTION STUDIEST32MH019105 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carol Suzanne Camlin, Glenn-Milo Santos · 1989 to 2026
$15.3M
Intramural NIH HHSNIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI095068NIAID NIH HHS R01-AI095068NIAID NIH HHS U01 AI069412NIAID NIH HHS U01 AI069418NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1-AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1-AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069418NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069470NICHD NIH HHS R25 HD045810NIGMS NIH HHS T32 GM008752NIMH NIH HHS P30 MH058107NIMH NIH HHS T32 MH019105
6 · The paper itself

Abstract

backgroundHIV Prevention Trials Network (HPTN) 061 enrolled black men who have sex with men in the United States. Some men with low/undetectable HIV RNA had unusual patterns of antiretroviral (ARV) drug use or had drugs detected in the absence of viral suppression. This report includes a comprehensive analysis of ARV drug use and drug resistance among men in HPTN 061 who were not virally suppressed.

methodsThe analysis included 169 men who had viral loads >400 copies per milliliter at enrollment, including 3 with acute infection and 13 with recent infection. By self-report, 88 were previously diagnosed, including 31 in care; 137 men reported no ARV drug use. Samples from these 169 men and 23 seroconverters were analyzed with HIV genotyping and ARV drug assays.

resultsForty-eight (28%) of the 169 men had ≥ 1 drug resistance mutation (DRM); 19 (11%) had multiclass resistance. Sixty men (36%) had ≥ 1 ARV drug detected, 42 (70%) of whom reported no ARV drug use. Nine (23%) of 39 newly infected men had ≥ 1 DRM; 10 had ≥ 1 ARV drug detected. Unusual patterns of ARV drugs were detected more frequently in newly diagnosed men than previously diagnosed men. The rate of transmitted drug resistance was 23% based on HIV genotyping and self-reported ARV drug use but was 12% after adjusting for ARV drug detection.

conclusionsMany men in HPTN 061 had drug-resistant HIV, and many were at risk of acquiring additional DRMs. ARV drug testing revealed unusual patterns of ARV drug use and provided a more accurate estimate of transmitted drug resistance.

Indexed as

Black or African AmericanDrug Resistance, ViralHomosexuality, MaleAdultAnti-HIV AgentsGenotypeHIV InfectionsHumansMaleAnti-HIV Agents

Identifiers

PMID25861015
PMCPMC4482803
OpenAlexW2034677588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.